Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence

Kieran, Mark W. ; Caron, Hubert ; Winther, Jeanette Falck ; Henderson, Tara O. ; Haupt, Riccardo ; Hjorth, Lars LU ; Hudson, Melissa M. ; Kremer, Leontien C.M. ; van der Pal, Helena J. and Pearson, Andrew D.J. , et al. (2021) In Pediatric Blood and Cancer 68(7).
Abstract

While considerable efforts and progress in our understanding of the long-term toxicities of surgery, radiation and chemotherapy in children with cancer have been made over the last 5 decades, there continues to be a wide gap in our knowledge of the long-term health impact of most novel targeted and immunotherapy agents. To address this gap, ACCELERATE, a multi-stakeholder collaboration of clinical and translational academics, regulators from the EMA and FDA, patient/family advocates and members spanning small biotechnology through to large pharmaceutical companies have initiated the development of an international long-term follow-up data registry to collect this important information prospectively. Providing critical safety data on the... (More)

While considerable efforts and progress in our understanding of the long-term toxicities of surgery, radiation and chemotherapy in children with cancer have been made over the last 5 decades, there continues to be a wide gap in our knowledge of the long-term health impact of most novel targeted and immunotherapy agents. To address this gap, ACCELERATE, a multi-stakeholder collaboration of clinical and translational academics, regulators from the EMA and FDA, patient/family advocates and members spanning small biotechnology through to large pharmaceutical companies have initiated the development of an international long-term follow-up data registry to collect this important information prospectively. Providing critical safety data on the long-term use of these approved and investigational therapies in children will support the regulatory requirements and labeling information. It will also provide the necessary insight to help guide physicians and families on the appropriateness of a targeted or immune therapy for their child and inform survivorship planning.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
author collaboration
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Childhood cancer, Immunotherapy, Long-term follow-up, Long-term survivor, Pediatric cancer, survivorship, Targeted therapy
in
Pediatric Blood and Cancer
volume
68
issue
7
article number
e29047
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:85104429487
  • pmid:33860611
ISSN
1545-5009
DOI
10.1002/pbc.29047
language
English
LU publication?
yes
id
91acc5ca-cf6f-46d4-b45a-6a924224b4a7
date added to LUP
2021-05-04 11:29:34
date last changed
2024-04-20 05:45:04
@misc{91acc5ca-cf6f-46d4-b45a-6a924224b4a7,
  abstract     = {{<p>While considerable efforts and progress in our understanding of the long-term toxicities of surgery, radiation and chemotherapy in children with cancer have been made over the last 5 decades, there continues to be a wide gap in our knowledge of the long-term health impact of most novel targeted and immunotherapy agents. To address this gap, ACCELERATE, a multi-stakeholder collaboration of clinical and translational academics, regulators from the EMA and FDA, patient/family advocates and members spanning small biotechnology through to large pharmaceutical companies have initiated the development of an international long-term follow-up data registry to collect this important information prospectively. Providing critical safety data on the long-term use of these approved and investigational therapies in children will support the regulatory requirements and labeling information. It will also provide the necessary insight to help guide physicians and families on the appropriateness of a targeted or immune therapy for their child and inform survivorship planning.</p>}},
  author       = {{Kieran, Mark W. and Caron, Hubert and Winther, Jeanette Falck and Henderson, Tara O. and Haupt, Riccardo and Hjorth, Lars and Hudson, Melissa M. and Kremer, Leontien C.M. and van der Pal, Helena J. and Pearson, Andrew D.J. and Pereira, Leonardo and Reaman, Gregory and Skinner, Roderick and Vassal, Gilles and Weiner, Susan L. and Horton Taylor, Danielle}},
  issn         = {{1545-5009}},
  keywords     = {{Childhood cancer; Immunotherapy; Long-term follow-up; Long-term survivor; Pediatric cancer; survivorship; Targeted therapy}},
  language     = {{eng}},
  month        = {{07}},
  number       = {{7}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Pediatric Blood and Cancer}},
  title        = {{A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence}},
  url          = {{http://dx.doi.org/10.1002/pbc.29047}},
  doi          = {{10.1002/pbc.29047}},
  volume       = {{68}},
  year         = {{2021}},
}